Market Insight: Ultragenyx Pharmaceutical Inc. (RARE)’s Notable Drop, Closing at 39.05

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In the latest session, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed at $39.05 down -9.44% from its previous closing price of $43.12. In other words, the price has decreased by -$9.44 from its previous closing price. On the day, 4.11 million shares were traded. RARE stock price reached its highest trading level at $41.0 during the session, while it also had its lowest trading level at $38.16.


For a deeper understanding of Ultragenyx Pharmaceutical Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.43. In the meantime, Its Debt-to-Equity ratio is 6.65 whereas as Long-Term Debt/Eq ratio is at 6.25.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.

On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.

On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 12 ’24 when Parschauer Karah Herdman sold 9,806 shares for $45.00 per share. The transaction valued at 441,270 led to the insider holds 57,981 shares of the business.

Sanders Corazon (Corsee) D. sold 1,737 shares of RARE for $71,391 on Jun 10 ’24. The Director now owns 7,248 shares after completing the transaction at $41.10 per share. On May 02 ’24, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 354 shares for $43.66 each. As a result, the insider received 15,456 and left with 48,431 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3246355200 and an Enterprise Value of 3763968256. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.33 while its Price-to-Book (P/B) ratio in mrq is 23.13. Its current Enterprise Value per Revenue stands at 8.504 whereas that against EBITDA is -6.833.

Stock Price History:

Over the past 52 weeks, RARE has reached a high of $54.56, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is -9.32%, while the 200-Day Moving Average is calculated to be -7.95%.

Shares Statistics:

For the past three months, RARE has traded an average of 754.15K shares per day and 1130660 over the past ten days. A total of 82.31M shares are outstanding, with a floating share count of 77.93M. Insiders hold about 6.26% of the company’s shares, while institutions hold 97.76% stake in the company. Shares short for RARE as of 1715731200 were 4337729 with a Short Ratio of 5.92, compared to 1713139200 on 4382486. Therefore, it implies a Short% of Shares Outstanding of 4337729 and a Short% of Float of 6.08.

Most Popular